Researchers at Icahn School of Medicine at Mount Sinai Report New Data on Type 1 Diabetes (Multicenter Evaluation of Ultra-rapid Lispro Insulin With Control-iq Technology In Adults, Adolescents, and Children With Type 1 Diabetes).

Researchers at the Icahn School of Medicine at Mount Sinai conducted a study to evaluate the safety and efficacy of using ultra-rapid lispro (URLi) insulin in the Tandem t:slim X2 insulin pump with Control-IQ 1.5 technology in individuals with type 1 diabetes (T1D). The trial included 179 participants with T1D, ranging in age from 6 to 75 years. The study found that URLi use in the insulin pump was safe for both adults and children with T1D, and participants reported improvements in quality of life. The research was supported by Tandem Diabetes Care, Inc. and Eli Lilly. [Extracted from the article]

Copyright of Medical Devices & Surgical Technology Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)